Resource Logo
NLM AIDSLINE

Failure of indirect fluorescent antibody (IFA) test to detect asymptomatic leishmania SP infection among HIV-infected people in Spain.




 

Int Conf AIDS. 1993 Jun 6-11;9(1):383 (abstract no. PO-B10-1485). Unique

OBJECTIVE: To assess the usefulness of Leishmania IFA test in detecting asymptomatic Leishmania sp infection in HIV-infected people who could benefit from early treatment in an endemic area. METHODS: Prospective follow-up of a cohort of 237 HIV-infected patients. Mean follow-up 18 mo (min: six mo). Anti-Leishmania IFA test was determined at entry and afterwards when clinically indicated. RESULTS: Risk practice was IVDU in 85.4%. CDC group: Fifty-two percent G.II, 41.6% G.IV. follow-up: None of the 237 patients had a positive Leishmania IFA test at entry (> or = 1:80). Six out of them being initially reported as indeterminate titer 1:40) were negative when repeated and did not develop visceral leishmaniasis (VL). During the follow-up period nine patients were diagnosed of VL with demonstration of the parasite in bone marrow examination or a positive culture. Seven out of them developed a positive leishmania IFA test. Their mean CD4 count (322.4 x 10(6)/L) was lower than the CD4 count of the global series (466.5) but the difference was not significative. CONCLUSIONS: 1) Asymptomatic Leishmania sp infection, in contrast with other well known opportunistic infections, seems to be extremely uncommon in HIV-infected People. 2) Most of the cases of HIV-related VL correspond to new infections rather than to reactivation. 3) VL, like tuberculosis, seems to occur relatively early in the course of HIV progression to symptomatic disease.

*AIDS-Related Opportunistic Infections/DIAGNOSIS *HIV Infections/COMPLICATIONS *Leishmaniasis/DIAGNOSIS *Leishmaniasis, Visceral/DIAGNOSIS



 




Information in this article was accurate in November 30, 1993. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.